US Patent

US8916195 — Sustained release formulation of naltrexone

Method of Use · Assigned to Orexigen Therapeutics Inc · Expires 2030-02-02 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided for administration.

USPTO Abstract

A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1639`	—

Patent Metadata

Patent number: US8916195
Jurisdiction: US
Classification: Method of Use
Expires: 2030-02-02
Drug substance claim: No
Drug product claim: No
Assignee: Orexigen Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.